COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer protein S6P mutant (F817P, A892P, A899P, A942P, K986P, V987P) with furin cleavage site mutation (R682G, R683S, R685S) & T4 fibritin trimerization motif

Order information

Package	Catalog No.	Price(In USD)	Qty (Quantity)	Sum(In USD)
1mg	GMP-V-2019nCoV-S-trimer-003-1mg	5990
10mg	GMP-V-2019nCoV-S-trimer-003-10mg	38790
100mg	GMP-V-2019nCoV-S-trimer-003-100mg	258000
≥100mg	GMP-V-2019nCoV-S-trimer-003-xmg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Accession Number	QHD43415.1
Expression platform	2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
Isotypes	Mamamlian (human cell)
Tag	C-His
Products description	Recombinant 2019-nCoV(SARS-CoV-2)e Spike Protein S1+S2 domain with furin cleavage site mutation (R682G, R683S, R685S) and S6P mutation (F817P, A892P, A899P, A942P, K986P, V987P) was expressed in mammanlian cell (human cells) expression system. The target gene encoding Met1-Gln1208 (R682G, R683S, R685S, F817P, A892P, A899P, A942P, K986P, V987P) was expressed with 6 HIS tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and S1/S2 cleavage site (furin cleavage sequence) mutation of PRRAR to PGSAS at residues 682–685 (R682G, R683S, R685S) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively. T4 fibritin trimerization motif is added to C-terminal of the protein to improve the stability of spike trimer protein.
Bioactivity validation	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
Purity	Purity: ≥95% (SDS-PAGE)
Application	Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass	136kDa
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer protein S6P mutant (F817P, A892P, A899P, A942P, K986P, V987P).

The target gene encoding Met1-Gln1208 (RR682G, R683S, R685S, F817P, A892P, A899P, A942P, K986P, V987P) was expressed with 6 HIS tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and S1/S2 cleavage site (furin cleavage sequence) mutation of PRRAR to PGSAS at residues 682–685 (R682G, R683S, R685S) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively. T4 fibritin trimerization motif is added to C-terminal of the protein to improve the stability of spike trimer protein.

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.

Validated in functional ELISA, other immunoassays, the antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.

Information of SARS-CoV-2 (2019nCOV) Spike protein trimer

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection.The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. The highly flexible Spike protein (S-protein), with its mobile domains, transitions from closed to open conformations to expose its receptor-binding site and, subsequently, from prefusion to postfusion conformations to mediate fusion of viral and cellular membranes. SARS-CoV-2 (2019nCoV) Spike protein (S-protein) derivatives are components of vaccine candidates and diagnostic assays, as well as tools for research into the biology and immunology of SARS-CoV-2. We designed Spike mutations that allow the production of thermostable, disulfide-bonded Spike-protein trimers that are trapped in the closed, prefusion state. Structures of the disulfide-stabilized and non-disulfide-stabilized proteins reveal distinct closed and locked conformations of the Spike protein trimer.

The thermostable, disulfide-bonded Spike-protein trimers construct we make is:
1) S1/S2 cleavage site (furin cleavage sequence) mutant: Modification of the coding sequence of the multibasic S1/S2 cleavage site (furin cleavage sequence) PRRAR to PGSAS at residues 682–685 (R682G, R683S, R685S).
2) S-P6 mutant: proline substitutions: F817P, A892P, A899P, A942P, K986P, V987P.
3) Trimerization statues: add exogenous trimerization signal peptides: T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus.

It has been demonstrated that the designed, thermostable, closed Spike trimer can be used in serological assays in COVID-19 test. This trimer protein has potential applications as a reagent for serology, virology and as an immunogen of COVID-19 related diagnostics and vaccine development. GeneMedi also offers pre-made gene ORF mutation plasmids of Spike trimer mutation(thermostable, disulfide-bonded Spike-protein trimers).

The pre-made gene ORF vector of Spike trimer mutation is Codon Optimized for mamamlian and can be used for mammalian expression.

GeneMedi also provides pre-made the lentivirus, adenovirus and AAV vector for the gene ORF plasmids of 2019 nCoV (SARS2 coronavirus).

Reference:
Xiong X, Qu K, Ciazynska KA, Hosmillo M, Carter AP, Ebrahimi S, Ke Z, Scheres SHW, Bergamaschi L, Grice GL, Zhang Y; CITIID-NIHR COVID-19 BioResource Collaboration, Nathan JA, Baker S, James LC, Baxendale HE, Goodfellow I, Doffinger R, Briggs JAG. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol. 2020 Oct;27(10):934-941. doi: 10.1038/s41594-020-0478-5. Epub 2020 Jul 31. PMID: 32737467; PMCID: PMC7116388.